Seegenschmiedt M H
Klinik für Radioonkologie, Strahlentherapie und Nuklearmedizin, Alfried-Krupp-von-Bohlen-und-Halbach-Krankenhaus, Essen-Rüttenscheid.
Strahlenther Onkol. 1998 Nov;174 Suppl 3:25-9.
The documentation of acute and chronic treatment sequelae is a decisive precondition for the appropriate evaluation of the treatment quality of any cancer therapy.
Interdisciplinary (inter)national efforts have resulted in a new consensus for recording of treatment sequelae in oncology. While the acute treatment side effects (day 1 to 90 after treatment) are recommended to be documented and evaluated using the Common Toxicity Criteria (CTC), for the chronic treatment side effects (day 91 and thereafter) the Late Effect Normal Tissue (LENT) criteria are to be implemented. The latter classification system allows to differentiate between the Subjective, Objective, Management and Analytic (SOMA) toxicity aspects. Both classification systems can be implemented not only for clinical applications using radiotherapy or chemotherapy alone but also for combinations with each other or with other treatment modalities. This allows for an effective interdisciplinary comparison between different treatment concepts not only within each institution but also in multicenter trials.
Prospective documentation and evaluation of treatment toxicity in oncology should be intensified and systematically included in future mono- and multi-institutional clinical trials.
急性和慢性治疗后遗症的记录是恰当评估任何癌症治疗质量的决定性前提条件。
跨学科(国际)努力已达成肿瘤学治疗后遗症记录的新共识。对于急性治疗副作用(治疗后第1天至90天),建议使用通用毒性标准(CTC)进行记录和评估;对于慢性治疗副作用(第91天及之后),则应采用晚期效应正常组织(LENT)标准。后一种分类系统能够区分主观、客观、管理和分析(SOMA)毒性方面。这两种分类系统不仅可用于单独使用放疗或化疗的临床应用,还可用于相互联合或与其他治疗方式联合的情况。这使得不仅在各机构内部,而且在多中心试验中,不同治疗概念之间能够进行有效的跨学科比较。
肿瘤学中治疗毒性的前瞻性记录和评估应得到加强,并系统地纳入未来的单机构和多机构临床试验。